Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 33 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF MelanomaCompletedNCT02159066Phase 2Results posted
• Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)CompletedNCT02157883Phase 1Results posted
• Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to ErlotinibCompletedNCT02155465Phase 1/2Results posted
• Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast CancerTerminatedNCT02154529Phase 1/2Results posted
• A Phase II, Single Arm Study of BGJ398 in Patients With Advanced CholangiocarcinomaTerminatedNCT02150967Phase 2Results posted
• Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)CompletedNCT02149108Phase 3Results posted
• Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung CancerTerminatedNCT02147990Phase 2Results posted
• A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background MethotrexateCompletedNCT02147587Phase 2Results posted
• Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic LeukemiaActive, not recruitingNCT02143414Phase 2Results posted
• Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell LymphomaCompletedNCT02142049Phase 1/2Results posted
• A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell CancerCompletedNCT02133742Phase 1Results posted
• Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain MetastasesTerminatedNCT02132598Phase 2Results posted
• LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapyTerminatedNCT02131155Phase 3Results posted
• A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT02130557Phase 3Results posted
• Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomasCompletedNCT02129647Phase 2Results posted
• Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaTerminatedNCT02129062Phase 2Results posted
• A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)CompletedNCT02127710Phase 2Results posted
• Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571TerminatedNCT02127372Phase 1/2Results posted
• Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential ThrombocythemiaCompletedNCT02124746Phase 2Results posted
• Afatinib in Advanced Refractory Urothelial CancerTerminatedNCT02122172Phase 2Results posted
• A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast CancerTerminatedNCT02120417Phase 2Results posted
• Study of Ruxolitinib in Colorectal Cancer PatientsTerminatedNCT02119676Phase 2Results posted
• A Study of Ruxolitinib in Pancreatic Cancer PatientsTerminatedNCT02119663Phase 3Results posted
• Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung CancerTerminatedNCT02119650Phase 2Results posted
• Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)TerminatedNCT02117479Phase 3Results posted
• An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary ObjectiveCompletedNCT02116803Phase 2/3Results posted
• Single Agent Regorafenib in Refractory Advanced Biliary CancersCompletedNCT02115542Phase 2Results posted
• Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to NilotinibTerminatedNCT02115386Phase 3Results posted
• c-Met Second-Line Hepatocellular CarcinomaCompletedNCT02115373Phase 1/2Results posted
• Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole AloneTerminatedNCT02115048Phase 2Results posted
• Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) NephropathyCompletedNCT02112838Phase 2Results posted
• Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell LymphomaCompletedNCT02112526Phase 1Results posted
• A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid MalignanciesCompletedNCT02108964Phase 1/2Results posted
• Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.TerminatedNCT02108951Phase 3Results posted
• Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02101775Phase 2Results posted
• Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and AdultsCompletedNCT02101736Phase 2Results posted
• Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MFCompletedNCT02101268Phase 3Results posted
• Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT02101021Phase 3Results posted
• Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaCompletedNCT02098538Phase 2Results posted
• Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD9291 in VolunteersCompletedNCT02096679Phase 1Results posted
• Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT02095132Phase 1/2Results posted
• A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibCompletedNCT02094573Phase 2Results posted
• Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive TumoursCompletedNCT02094261Phase 2Results posted
• Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-StudyTerminatedNCT02092961Phase 2Results posted
• Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid ArthritisCompletedNCT02092467Phase 4Results posted
• Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid LeukemiaCompletedNCT02092324Phase 2Results posted
• A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)TerminatedNCT02091752Phase 2Results posted
• My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsCompletedNCT02091141Phase 2Results posted
• Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung CancerTerminatedNCT02087241Phase 2Results posted
• A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung CancerTerminatedNCT02087176Phase 2Results posted
• A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) MyelofibrosisCompletedNCT02087059Phase 3Results posted
• A Study of Regorafenib in Advanced Pancreatic Cancer PatientsCompletedNCT02080260Phase 2Results posted
• Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)CompletedNCT02077192Phase 3Results posted
• Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02077166Phase 1/2Results posted
• First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular DegenerationCompletedNCT02076919Phase 1Results posted
• A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)CompletedNCT02076412Phase 3Results posted
• A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)CompletedNCT02076399Phase 3Results posted
• A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer ParticipantsCompletedNCT02075840Phase 3Results posted
• Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With PaclitaxelCompletedNCT02073487Phase 2Results posted
• Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast CancerCompletedNCT02066532Phase 1/2Results posted
• A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX AloneCompletedNCT02066389Phase 2Results posted
• Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive FibromatosisCompletedNCT02066181Phase 3Results posted
• Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis ParticipantsCompletedNCT02065700Phase 2Results posted
• Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)CompletedNCT02060370Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal CancerTerminatedNCT02059265Phase 2Results posted
• Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and ThrombocytopeniaTerminatedNCT02055781Phase 3Results posted
• A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line ChemotherapyCompletedNCT02053376Phase 2Results posted
• A Study of TAS-120 in Patients With Advanced Solid TumorsCompletedNCT02052778Phase 1/2Results posted
• Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue SarcomaCompletedNCT02050919Phase 2Results posted
• Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.CompletedNCT02049450Phase 2Results posted
• An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid ArthritisCompletedNCT02049138Phase 2Results posted
• Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT02048813Phase 3Results posted
• Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced AngiosarcomaCompletedNCT02048722Phase 2Results posted
• SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma SubtypesCompletedNCT02048371Phase 2Results posted
• A Phase II Study of Dacomitinib in Progressive Brain MetastasesTerminatedNCT02047747Phase 2Results posted
• Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) MutationsCompletedNCT02044380Phase 3Results posted
• Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in JapanCompletedNCT02042014Phase 3Results posted
• Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory BrcaCompletedNCT02041429Phase 1/2Results posted
• LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibCompletedNCT02040870Phase 1/2Results posted
• (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD PositiveCompletedNCT02039726Phase 3Results posted
• Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.CompletedNCT02038036Phase 3Results posted
• Cabozantinib in Recurrent/Metastatic Merkel Cell CarcinomaTerminatedNCT02036476Phase 2Results posted
• ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic LeukemiaActive, not recruitingNCT02029443Phase 1/2Results posted
• Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT02024087Phase 1/2Results posted
• Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal AdenocarcinomaCompletedNCT02023333Phase 2Results posted
• Sorafenib for Hepatopulmonary SyndromeTerminatedNCT02021929Phase 2Results posted
• Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid TumoursCompletedNCT02020577Phase 1Results posted
• A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell CancerCompletedNCT02019693Phase 2Results posted
• Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal TumorsCompletedNCT02015065Phase 2Results posted
• Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02014558Phase 1/2Results posted
• A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to ChemotherapyCompletedNCT02013206Phase 2Results posted
• A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid LeukemiaCompletedNCT02011945Phase 1Results posted
• Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsTerminatedNCT02004028Phase 2Results posted
• Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)CompletedNCT02001181Phase 2Results posted
• Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese PopulationCompletedNCT02000531Phase 4Results posted
• Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)CompletedNCT01999985Phase 1Results posted
• A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid TumorsCompletedNCT01999972Phase 1Results posted
• A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01996332Phase 2Results posted
• Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCTerminatedNCT01995058Phase 2Results posted
• Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)TerminatedNCT01994590Phase 2Results posted

← Tyrosine Kinase Inhibitors overview